MAIA•benzinga•
MAIA Biotechnology Says New Partial Response Identified In Patient After 20 Months Of Treatment In Phase 2 THIO-101 Clinical Trial Evaluating Ateganosine, Sequenced With Regeneron's Immune CPI Libtayo In NSCLC Patients
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 5, 2025 by benzinga